Open Access Repository

The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern

Prasanna, T, Karapetis, CS, Roder, D, Tie, J, Padbury, R, Price, T, Wong, R, Shapiro, J, Nott, L, Lee, M, Chua, YJ, Craft, P, Piantadosi, C, Sorich, M, Gibbs, P and Yip, D 2018 , 'The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern' , Acta Oncologica, vol. 57, no. 11 , pp. 1438-1444 , doi: 10.1080/0284186X.2018.1487581.

Full text not available from this repository.

Abstract

Background: Pattern of spread in patients with metastatic colorectal cancer (mCRC) is variable and may reflect different biology in subsets of patients. This is a retrospective study to explore the outcome of patients with mCRC based on their site of metastasis at diagnosis and to explore the association between tumor characteristics [KRAS/RAS, BRAF, mismatch repair (MMR) status, site of primary] and the site of metastasis.Methods: Patients from two Australian databases were divided into six groups based on site of metastasis at time of diagnosis of metastatic disease; lung-only, liver-only, lymph node-only or any patients with brain, bone or peritoneal metastases. Primary endpoint was overall survival (OS) of each cohort compared with the rest of the population. A Mantel-Haenszel chi-squared test used to explore the association between site of metastasis and selected tumor characteristics.Results: Five thousand nine hundred and sixty-seven patients were included. In a univariate analysis, median OS was significantly higher when metastases were limited to lung or liver and shorter for those with brain, bone or peritoneal metastases (p p p = .004) and liver (RR = 0.7, p = .005) limited metastases. Lung-only metastases were more frequent with KRAS/RAS mutation (RR = 1.4, p = .007). Left colon tumors were associated with bone (RR = 1.6, p p = .001) while peritoneal spread was less frequent compared with right colon tumors (RR = 0.6, p p = .002, 1.7; p p p = .01).Conclusion: Survival duration with mCRC is related to the site of metastases with lung limited disease showing a more favorable survival outcome compared to other single metastatic site disease. The BRAF mutation and primary rectal cancer were associated with poor prognostic metastatic sites.

Item Type: Article
Authors/Creators:Prasanna, T and Karapetis, CS and Roder, D and Tie, J and Padbury, R and Price, T and Wong, R and Shapiro, J and Nott, L and Lee, M and Chua, YJ and Craft, P and Piantadosi, C and Sorich, M and Gibbs, P and Yip, D
Journal or Publication Title: Acta Oncologica
Publisher: Taylor & Francis As
ISSN: 0284-186X
DOI / ID Number: 10.1080/0284186X.2018.1487581
Copyright Information:

Copyright 2018 Acta Oncologica Foundation

Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP